Official announcements on ACS Biomed's clinical development, regulatory milestones, commercial agreements and scientific research.
International business development activities continue as the company strengthens its global commercial and pharmaceutical network.
Read More
Observational clinical experience collected by an independent physician contributes additional real-world insights into the use of ErpeCream® in patients with recurrent HSV infections.
Read More
International multicentre clinical trial supports the pharmaceutical development of ErpeCream® and future regulatory strategy.
Read More
Regulatory submissions in Mexico and Brazil represent the first step towards commercialisation across key Latin American markets.
Read More
Exclusive agreement covering Mexico, Brazil, Venezuela, the Dominican Republic and Central America with contracted minimum purchase obligations of €10.6 million.
Read More
New topical formulation extends the company's proprietary HSV platform and strengthens its international commercial offering.
Read More
Long-term stability studies confirm the robustness of ErpeCream® under demanding climatic conditions, supporting international distribution and future regulatory activities.
Read More
European and UK notifications establish the commercial foundation for market expansion while supporting ACS Biomed's long-term pharmaceutical development strategy.
Read More
Studies conducted by the University of Ferrara provide independent scientific evidence supporting the antiviral activity of ACS Biomed's proprietary formulation.
Read MorePress releases may reference activities and agreements at various stages. Dates and forward-looking statements are subject to change.